Results 101 to 110 of about 528,594 (306)

Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma

npj Precision Oncology
Tumour mutation burden (TMB) is a promising biomarker in predicting immunotherapy response, yet its reproducibility across target panels needs to be established. This study assessed the reproducibility of TMB estimates in melanoma using TruSight Oncology
Yizhe Mao, Tuba N. Gide, Nigel G. Maher, Danielle Vignati, Andrea Boutros, Paola Cornejo-Páramo, Alison J. Potter, Matteo S. Carlino, Elizabeth C. Paver, Hazel Burke, Alexander M. Menzies, Serigne N. Lo, Inês Pires da Silva, Richard A. Scolyer, Georgina V. Long, Ismael A. Vergara, James S. Wilmott   +16 more
doaj   +1 more source

30 | Sonidegib for nevoid basal cell carcinoma (Gorlin) syndrome and EADO stage IIb sporadic basal cell carcinomas: a phase II study (SIBLINGS trial)

Dermatology Reports
Background: Nevoid Basal Cell Carcinoma Syndrome (NBCCS), or Gorlin syndrome, is a rare genetic condition characterized by multiple basal cell carcinomas (BCCs). Some sporadic BCC patients present multiple lesions, classified as difficult-to-treat (EADO
Italian Melanoma Intergroup
doaj   +1 more source

Bioorthogonal Photoactivation of 2‐Nitrobenzyl Caged Doxorubicin Anticancer Prodrugs on Gold Nanostars

Advanced Materials, EarlyView.
Bioorthogonal chemistry was applied to intracellularly photoactivate Doxorubicin (Dox) using gold nanostars (AuNSt) and near‐infrared (NIR) light. Two prodrugs were used: one photoactivatable, masked with 2‐nitrobenzyl carbamate (proDox1) and another photolabile, masked with 2‐nitrobenzyl diol (proDox2), which was attached to the AuNSt surface.
Juan José Esteve‐Moreno, Andrea Escudero, Oscar Ferreira Silvestre, José Manuel Terrés, Mónica Gorbe, Eva Garrido, Carlos Renero‐Lecuna, Judith Langer, María Alfonso, Javier Ibañez, Félix Sancenón, Roberto Cao‐Milán, Luis M. Liz‐Marzán, Alba García‐Fernández, Andy Hernández‐Montoto, Ramón Martínez‐Máñez   +15 more
wiley   +1 more source

Melanoma

The Oncologist, 2001
Abstract The presentations at the American Society of Clinical Oncology 2001 meeting reported or updated the results of phase I, II, and III randomized trials and also reported important meta-analyses and retrospective studies impacting on the management of patients with melanoma.
openaire   +2 more sources

32 | Tebentafusp in metastatic uveal melanoma: 3 years of real world data and insights from liquid biopsy

Dermatology Reports
Background: Real world data are needed to optimize the use of Tebentafusp, the first agent improving the overall survival in metastatic uveal melanoma (mUM) patients even if progressive disease (PD) is the best response. Methods: Baseline clinical data,
Italian Melanoma Intergroup
doaj   +1 more source

Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects

Advanced Materials, EarlyView.
Mesoporous silica nanoparticles offer unique properties like high surface area, tunable pores, and functionalization. They excel in drug delivery, tissue engineering, and stimuli‐responsive therapies, enabling targeted and controlled treatments. With roles in cancer therapy and diagnostics, their clinical translation requires addressing challenges in ...
Miguel Manzano, María Vallet‐Regí
wiley   +1 more source

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network [PDF]

, 2013
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Berking, Carola, Armin Justich (103646), Simone M. Goldinger, Daniela Göppner, Lucie M Heinzerling, Stephan Grabbe (103633), Clemens L. Bockmeyer, Robert Caroline, Thomas Eigentler, Christine Mateus (103663), Moos, Roger von, Loquai Carmen, Gerold Schuler, Dirk Schadendorf (103684), Christina Klein, Pätzold, Sylvie, Hundorfean, Gheorghe, Beatrice Schuler-Thurner, Göppner Daniela, Ralf Gutzmer (103628), Patrik Weder, Robert, Caroline, Bockmeyer, Clemens L., Dirk Schadendorf, Kaehler, Katharina C., Thomas Eigentler (103619), Katharina C. Kaehler, Gheorghe Hundorfean, Christine Mateus, Simone M. Goldinger (103594), Claus Garbe, Satzger, Imke, Ralf Gutzmer, Sylvie Paetzold (103676), Peter Mohr, Uwe Trefzer, Voskens, Caroline J, Carmen Loquai (103597), Bockmeyer Clemens L., Vaubel, Julia, Jens Ulrich, Wilhelm, Tabea, Bockmeyer, Clemens Luitpold, Julia Vaubel, Hauschild Axel, Mohr, Peter, Gheorghe Hundorfean (103642), Caroline J. Voskens, Justich, Armin, Hauschild, Axel, Fluck Michael, Loquai, Carmen, Schadendorf, Dirk, Beatrice Schuler-Thurner (103693), Satzger Imke, Göppner, Daniela, Carola Berking, Weder Patrik, Hundorfean Gheorghe, Eigentler, Thomas Kurt, Grabbe, Stephan, Ulrich Jens, Armin Justich, Rüdiger Hein (71354), Garbe Claus, Ulrich, Jens, Eigentler Thomas, Schadendorf Dirk, Gutzmer Ralf, Mateus Christine, Imke Satzger, Weder, Patrik, Ullrich Keller (103650), Lucie M. Heinzerling (103723), Gerold Schuler (103690), Axel Hauschild (103637), Christina Klein (103657), Michael Fluck, Tanja Bergmann (103612), Axel Hauschild, Paetzold Sylvie, Katharina C Kaehler, Wilhelm Tabea, Keller, Ullrich, Schlaeppi Marc, Goldinger, Simone M., Claus Garbe (48881), Berking Carola, Heinzerling, Lucie, von Moos Roger, Simone M Goldinger, Trefzer Uwe, Uwe Trefzer (72075), Rüdiger Hein, Mateus, Christine, Caroline Robert, Tabea Wilhelm (103712), Schuler Gerold, Dummer, Reinhard, Schuler-Thurner Beatrice, Roger von Moos, Hein Rüdiger, Eigentler, Thomas, Paetzold, Sylvie, Caroline J Voskens, Caroline J. Voskens (103590), Schuler-Thurner, Beatrice, Roger von Moos (103705), Patrik Weder (103709), Lucie M. Heinzerling, Kaehler, Katharina C, Voskens, Caroline J., Fluck, Michael, Imke Satzger (103681), Schuler, Gerold, Tanja Bergmann, Marc Schlaeppi (103687), Bergmann, Tanja Regina, Julia Vaubel (103700), Bergmann Tanja, Heinzerling, Lucie M., Stephan Grabbe, Klein Christina, Caroline Robert (103600), Carola Berking (103608), Kähler, Katharina C., Peter Mohr (103669), Klein, Christina, Tabea Wilhelm, Reinhard Dummer (103718), Goldinger Simone M., Reinhard Dummer, Marc Schlaeppi, Gutzmer, Ralf, Hein, Rüdiger, Clemens L Bockmeyer, Sylvie Paetzold, Michael Fluck (103622), Kaehler Katharina C., Justich Armin, Voskens Caroline J., Carmen Loquai, Vaubel Julia, Grabbe Stephan, Keller Ullrich, Mohr Peter, Jens Ulrich (103696), Trefzer, Uwe, Katharina C. Kaehler (103604), Bergmann, Tanja, Heinzerling Lucie M., Dummer Reinhard, et al, Goldinger, Simone M, Daniela Göppner (103715), Garbe, Claus, Clemens L. Bockmeyer (103616), Schlaeppi, Marc, Ullrich Keller   +158 more
core   +1 more source

35 | Real-world outcomes of targeted therapy in stage IV melanoma after relapse on adjuvant dabrafenib and trametinib: insights from a single-center cohort

Dermatology Reports
Background: Adjuvant dabrafenib and trametinib (DT) reduce relapse risk in stage III BRAF-mutant melanoma, but data on recurrence patterns and management after relapse remain scarce.
Italian Melanoma Intergroup
doaj   +1 more source

Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors

Advanced Science, EarlyView.
Type I interferon (IFN‐I) signaling promotes p21‐dependent cell cycle arrest in senescent tumor‐specific memory T cells, resulting in poor proliferative responses and solid tumor regression during cancer vaccination. Conversely, IFNα/β receptor blockade reinvigorates T cell proliferation to regress solid tumors and is more effective with increasing ...
Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan   +4 more
wiley   +1 more source

27 | Real-world data for malignant melanoma stage II adjuvant therapy

Dermatology Reports
Background: Malignant melanoma (MM) is an aggressive cancer with high metastatic potential from early stages. Stage IIB/C MM shows overall survival lower than stage IIIA, with high recurrence risk. Recently, 1-year pembrolizumab or nivolumab was approved
Italian Melanoma Intergroup
doaj   +1 more source